PipelineReview.com6m
FDA Approves First Treatment for Niemann-Pick Disease, Type C
SILVER SPRING, MD, USA I September 20, 2024 I Today, the U.S. Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Niemann-Pick disease, type C (NPC).
PipelineReview.com7d
Radiant Bio Closes $35 Million Series A Financing to Advance Therapeutic Pipeline with Its Proprietary Multabody™ Platform
Funding co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures to advance a new class of multi-functional biologics ...
PipelineReview.com8d
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
PARIS, France and TARRYTOWN, NY, USA I 11, 2024 I A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key ...
PipelineReview.com8d
Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
PARIS, France, and HOUSTON, TX, USA I 12, 2024 I As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi ...
PipelineReview.com8d
IGI Announces Publication in Nature Cancer on ISB 2001, IGI’s Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma
NEW YORK, NY, USA I 11, 2024 I Ichnos Glenmark Innovation (IGI), an alliance between Ichnos Sciences Inc., a global fully-integrated clinical-stage ...
PipelineReview.com7d
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 ― ...
PipelineReview.com8d
Depemokimab late-breaking data presented at ERS show a 54% reduction in severe asthma exacerbations
LONDON, UK I 09, 2024 I GSK plc (LSE/NYSE: GSK) today presented the full results from the SWIFT-1 and SWIFT-2 phase III clinical trials which ...
PipelineReview.com8d
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
MUNICH & GARCHING, Germany & LAUSANNE, Switzerland I 12, 2024 I ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical ...
PipelineReview.com9d
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
RIDGEFIELD, CT, USA I 9, 2024 I Boehringer Ingelheim reports positive results from a Phase Ib primary analysis of Cohort 1 of the Beamion LUNG-1 ...
PipelineReview.com9d
New results from the Investigational agent BAY 2927088 in HER2-mutant non-small cell lung cancer (NSCLC) presented at WCLC
BERLIN, Gwrmany I September 09, 2024 I Bayer announced encouraging results from the expansion part of the ongoing Phase I/II SOHO-01 study evaluating the safety and preliminary efficacy of BAY 2927088 ...
PipelineReview.com9d
Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke
COLUMBUS, OH, USA I September 10, 2024 I Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy, today announced that the first ...
PipelineReview.com9d
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
NORTH CHICAGO, IL, USA I 9, 2024 I AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will ...